The company has registered total income of Rs. 3,847 crores for Q4 FY21, up by 3% on a y-o-y basis from Rs. 3,752 crores registered during corresponding period of the previous year
Consequently, AstraZeneca India and Sun Pharma have now discontinued the Distribution Agreement signed in 2016 and have entered into a Transition Supply Agreement with effect from 28th May 2021
It posted net profit of Rs.188.77 crores for the period ended March 31, 2020.
Posaconazole is a triazole antifungal agent indicated for treating mucormycosis patients
The company has reported total income of Rs.826.40 crores for FY 2020-21
The company plans to enter the EU markets in FY22
The company reported total income of Rs.455.28 crores during the 12 months period ended March 31, 2021
The company has posted net loss of Rs. 99.54 crores for the period ended March 31, 2020
The outlook for the US business remains good as respiratory pipeline (gAbraxane, gAdvair, gDulera) adds medium-term growth visibility.
India sales grew 23.5% YoY with consolidation of Wockhardt products
Subscribe To Our Newsletter & Stay Updated
